12th Annual Biologics Development & Drug Delivery Forum

14-15 June 2021 | A Virtual Event

Heinrich Haas

Vice President Formulation and Drug Delivery,    BioNTech

"Improving the Drug Delivery of mRNA Nanotherapeutics "

Paul Wassman, PhD

PSenior Principal Scientist, NIBR Biologics Center (NBC) Novartis Pharma

"Benefits and Challenges of Early Stability Assessments for Complex Protein Modalities "

" Strategies for Developing High Concentration Formulation for Monoclonal Antibodies and Biosimilars "

Head of Formulation and Analytical Development    Ichnos Sciences

Sachin Dubey

 For registration details and multiple attendee discounts, please contact:

Ayis Panayi


Ahmad S. Sediq, PH.D

Principal Scientist/ Senior Group Leader

"Challenges in the intravitreal (IVT) drug product development."

In this premium marcus evans event, key industry leaders from the Pharma and Life Sciences Industry are gathered together

Interested? Do you feel you will benefit?


© Copyright 2021 marcus evans conferences


One of the topics you will present includes the advantages of using micro fluidic technology. What do you think will be the future of this technology and what is its progress in the last years?

Microfluidics is a technique, which deals with flow of fluids within micron-sized channels and provides a platform where nanomedicines can be manufactured in a controlled manner. The microfluidics market includes drug discovery, drug delivery, and in-vitro diagnostics, among many others. Microfluidics have also all the potential to be used in the fight against a pandemic for the manufacturing of vaccines or rapid diagnosis.

What are the advantages of Polymer & lipid-based Nanomedicines for imaging or treatment or targeting?

 There are already FDA approved lipid formulations and lipid nanoparticles which are essential to the Moderna and Pfizer/BioNTech vaccines. Moreover, PLGA is FDA-approved copolymers for drug delivery applications. Lipid nanoparticles have the advantages that they are biocompatible and biodegradable, contain low toxicity, possess possibility of controlled and modified drug release, and are able to be loaded with drugs or biologics, while Polymeric nanoparticles are simple to synthesize, have higher stability and  sustained drug release).

Lipid nanoparticles became very important and got a lot of global interest because of the COVID-19 vaccine development. Why are they so important for these vaccines?

Over 90 vaccines are under development for COVID-19 across the world. Without the use of lipid nanoparticles, there would be no possible to deliver mRNA, therefore, having a successful vaccine for COVID.

How optimised can vaccine delivery be using lipid nanoparticles?

Microfluidics, can be used for drug discovery and development. Lipid nanoparticles, such as liposomes and solid lipid nanoparticles, can provide efficient delivery of mRNA and SiRNA.

How is the overall microfluidic technology process going to overpass other technologies in Drug Delivery?

Microfluidics is faster than traditional formulations (e.g., from couple of hours now only takes a few minutes) and since small amounts of reagents are required is also good for the environment.

What, for you, are the benefits of attending the 12th Annual Biologics Development & Drug Delivery Forum and what can attendees expect to learn from your session?

This is the 4th time that I am attending this meeting. Excellent sessions and opportunities for network. I have forged strong collaborations and good friendships throughout all these years attending the Forum

Which session are you most looking forward to and why?

 For all the sessions!  I will try my best to attend all since are hot topics and previous years all talks were amazing.

Prior to the long-awaited 12th Annual Biologics Formulation Development & Drug Delivery Forum, we have conducted an interview with Dimitrios Lamprou, Reader & MSc  Director School of Pharmacy, Queen's University, Belfast to understand better the advantages of using microfluidic technology, as well as the technology's progress and future

Dimitrios Lamprou is one of our speakers!

Dimitrios Lamprou will be presenting during the second day, 15th of June at  11:00am.
Case Study: Microfluidics for Drug and Vaccine Delivery 

• Advantages of microfluidic technology

 • Polymer & lipid-based Nanomedicines for imaging or treatment or targeting 

• Surface modification for cancer treatment/targeting 

• Vaccine delivery using lipid nanoparticles 

• Continues manufacturing